PISCATAWAY, N.J., April 14, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced its 2025 Environmental, Social, and Governance (ESG) Report, positioning the company at the forefront of ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...

Genscript Biotech (HK:1548) has released an update. Genscript Biotech Corporation announced the unaudited financial results for the third quarter of 2024 for its associate, Legend Biotech Corporation, ...

Good day and thank you for standing by. Welcome to Genscript Biotech 2025 Interim Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, ...

Recent price moves and business snapshot Genscript Biotech (SEHK:1548) has seen the stock slip about 0.5% on the day and roughly 5.6% over the past week, while posting a gain of around 13% over the ...

Good day, and thank you for standing by. Welcome to GenScript Biotech Annual Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now ...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, ...

In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...

(Reuters) -The U.S. House of Representatives committee on China on Tuesday sent a letter to the directors of the FBI and national intelligence, renewing its concerns about GenScript Biotechnology's ...

Earnings call GenScript's 2025 revenue surged 61.4% YoY to $959.5M, with adjusted net profit up 285% to $230.3M, fueled by strong segment performance and a major licensing deal. Despite a non-cash ...

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...